Exploiting the Immune Microenvironment Variation in Subtypes of Metastatic Prostate Cancer
Abstract
SPECIFIC AIMS and STUDY DESIGN: Aim 1: To define the immune cell types and tumor-derived cytokine effectors in specific phenotypes of mPC. This objective will validate recent findings in our group which determined differential expression of immune markers in DNPC when compared to other mPC phenotypes by applying Digital Spatial Profiling, multi-plex immunohistochemistry and digital cytometry technologies. Aim 2: To determine if tumor phenotype dictates the immune cell composition of the TME. The approach will focus on PDX models of mPC and assess whether tumor phenotype can dictate immune composition by utilizing humanized mouse models. Aim 3: Determine if therapeutics directed toward PC subtype-associated immune characteristics results in PC subtype-specific responses. The approach will utilize existing clinical therapeutics to assess efficacy in reducing tumor growth in mPC. I will determine the effect of anti-IL1R and anti-B7-H3 monoclonal antibodies (e.g. Anakinra and enoblituzumab) on tumor growth in three different PDX phenotypes of CRPC: androgen receptor positive, neuroendocrine and double-negative PCs.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2022
- Accession Number
- AD1173840
Entities
People
- Lauren Brady
Organizations
- Fred Hutchinson Cancer Center